5 ms·
What's the plan for the rest of the money, grants ?
by ig1 12y ago
What's the plan for the rest of the money, grants ?
- dnautics 12y agoGrants and big donors to push through preclinical and a for profit partner for clinical is my vision, but I am open minded to alternatives.
- thefreeman 12y agoDoesn't that fall apart when the for profit partner needs to pay the other $990 million dollars and then still cannot patent the drug?
- dnautics 12y agoI don't know. It's certainly a risk, but there's only one way to find out. I think there are companies willing to do it (cipla is one that I'm thinking about approaching).
- avivo 12y agoI'd like to see more of a potential plan here - otherwise I'm afraid that making a drug un-patentable would make it /less/ likely that it goes to market. I believe I've seen evidence of exactly that happening as margins for a drug are very low if it can't be protected (via IP), and the cost to bring a drug to market is so high. I see many problems with current IP system - but I don't see how this is avoidable in a completely commoditizable generic drug market. If I'm making some incorrect assumptions here, I'd love to know!
- dnautics 12y ago> I'm afraid that making a drug un-patentable would make it /less/ likely that it goes to market This is definitely a possible outcome. http://biz.yahoo.com/p/5qpmu.html http://biz.yahoo.com/p/5qpmu.html generics manufacturers make ~ 6% margin, which is basically "what most businesses make". "Drug manufacturers - Major" make 20% margin. Keep in mind also that big pharma spends about as much on advertising as they do on R&D.